血清MMP7与非糖尿病一般人群肾小球滤过率加速下降相关
在1627名50-64岁无糖尿病、肾脏或心血管疾病的一般人群中,基线血清MMP7每升高1个标准差与GFR下降更快相关(-0.23 mL/min/1.73 m2/年,95%CI -0.34至-0.12),并增加加速GFR下降和发生CKD的风险;MMP2和TIMP1无此关联。
要点
- 基线血清MMP7升高与中年非糖尿病人群GFR加速下降独立相关。
- MMP7每升高1个标准差,加速GFR下降风险OR为1.58(95%CI 1.30-1.93)。
- MMP2和TIMP1与GFR下降及CKD发生无关。
核心结论
- 促纤维化生物标志物MMP7(而非MMP2或TIMP1)与中年一般人群加速GFR下降和发生CKD的风险增加相关。
研究设计与样本
- 基于肾脏碘海醇清除率调查(Renal Iohexol Clearance Survey),纳入1627名50-64岁无自报糖尿病、肾脏或心血管疾病者,中位随访5.6年后1324人完成随访GFR测量。
- 采用线性混合模型和逻辑回归分析评估MMP7、MMP2和TIMP1与平均GFR下降率、加速GFR下降风险及发生CKD的关联。
主要发现
- MMP7每升高1个标准差与更陡的GFR下降率相关:-0.23 mL/min/1.73 m2/年(95%CI -0.34至-0.12)。
- 在调整年龄、性别、基线GFR、ACR和心血管危险因素的模型中,MMP7每升高1个标准差与加速GFR下降风险增加相关,OR 1.58(95%CI 1.30-1.93)。
- 同一模型中,MMP7每升高1个标准差与发生CKD风险增加相关,OR 1.45(95%CI 1.05-2.01)。
- MMP2和TIMP1与GFR下降或发生CKD无关联。
关键数值与推荐
- 加速GFR下降定义为GFR斜率位于最陡的10%:≥1.8 mL/min/1.73 m2/年。
- 发生CKD定义为GFR <60 mL/min/1.73 m2和/或尿白蛋白与肌酐比值(ACR)≥3.0 mg/mmol。
临床怎么用
- 在中年非糖尿病人群中,血清MMP7可作为识别GFR加速下降和CKD发生高风险个体的潜在生物标志物。
- MMP2和TIMP1在此人群中未显示与GFR下降或CKD发生的关联,不推荐用于风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Age-related reduction of glomerular filtration rate (GFR) is a major contributor to the global chronic kidney disease (CKD) epidemic. We investigated whether baseline serum levels of the pro-fibrotic matrix metalloproteinase 2 (MMP2), MMP7 and their inhibitor, tissue inhibitor of metalloproteinase 1 (TIMP1), which mediates fibrosis development in aging animals, were associated with GFR decline in a general non-diabetic population. METHODS: In the Renal Iohexol Clearance Survey, we measured GFR using iohexol clearance in 1627 subjects aged 50-64 years without self-reported diabetes, kidney or cardiovascular disease. After a median of 5.6 years, 1324 had follow-up GFR measurements. Using linear mixed models and logistic regression analyses, we evaluated the association of MMP7, MMP2 and TIMP1 with the mean GFR decline rate, risk of accelerated GFR decline (defined as subjects with the 10% steepest GFR slopes: ≥1.8 mL/min/1.73 m2/year) and incident CKD [GFR <60 mL/min/1.73 m2 and/or urinary albumin to creatinine ratio (ACR) ≥3.0 mg/mmol]. RESULTS: Higher MMP7 levels (per standard deviation increase of MMP7) were associated with steeper GFR decline rates [-0.23 mL/min/1.73 m2/year (95% confidence interval -0.34 to -0.12)] and increased risk of accelerated GFR decline and incident CKD [odds ratios 1.58 (1.30-1.93) and 1.45 (1.05-2.01), respectively, in a model adjusted for age, sex, baseline GFR, ACR and cardiovascular risk factors]. MMP2 and TIMP1 showed no association with GFR decline or incident CKD. CONCLUSIONS: The pro-fibrotic biomarker MMP7, but not MMP2 or TIMP1, is associated with increased risk of accelerated GFR decline and incident CKD in middle-aged persons from the general population.
引用
- Enoksen IT, Svistounov D, Norvik JV, et al. Serum matrix metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population. Nephrol Dial Transplant. 2022. PMID: 34436577. doi:10.1093/ndt/gfab251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。